Apellis and Beam Sign a Five-Year Research Collaboration to Discover Novel Therapies for Complement-Driven Diseases
Shots:
- Beam to receive $50M up front and $25M as near-term milestones & will be eligible to receive other milestones along with royalties on sales- following the exercise of the option. The companies will work on 6 research programs focusing on C3 & other complement targets in the eye- liver- and brain
- Apellis holds exclusive rights to license each of the 6 programs & responsible for subsequent development. Beam may elect to enter a 50-50 co-development & co-commercialization agreement with Apellis for one of the programs licensed under the collaboration
- Beam will utilize its base editing technology and conduct preclinical research on up to 6 base editing programs. The companies can extend the collaboration up to 2yrs. on a per year and program-by-program basis
Ref: Apellis | Image: Apellis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com